This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?
by Moumi Mondal
Medpace posted record Q2 awards and a stronger book-to-bill ratio, but can backlog conversion and study timing turn renewed demand into stronger 2027 growth?
MEDPPositive Net Change ICLRPositive Net Change IQVPositive Net Change
earnings-performance medical medical-devices
CVS Health Q2 Earnings and Revenues Top Estimates, Stock Climbs
by Zacks Equity Research
CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.
CVSNegative Net Change LHPositive Net Change DGXPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
Should You Buy CNH Industrial (CNH) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CNHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
What's in Store for These 4 Healthcare Companies This Earnings Season?
by Indrajit Bandyopadhyay
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.
MCKPositive Net Change CORPositive Net Change PACBPositive Net Change SOLVNegative Net Change
medical medical-devices
RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up
by Zacks Equity Research
Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.
RVTYPositive Net Change CAHPositive Net Change MCKPositive Net Change WSTPositive Net Change
earnings medical medical-devices
BTSG Raises 2026 Guidance as Specialty and Home Health Drive Growth
by Urbi Guha
BrightSpring beat second-quarter estimates and raised its 2026 outlook as specialty, infusion and home health growth lifted margins and EBITDA.
BTSGNegative Net Change OPCHNegative Net Change AVAHNegative Net Change
medical medical-devices
Is BTSG a Buy as Rapid Growth Collides With Its Premium Valuation?
by Urbi Guha
BrightSpring's broad-based growth and margin gains strengthen its outlook, but a premium valuation leaves little room for execution missteps.
BTSGNegative Net Change PNTGNegative Net Change OPCHNegative Net Change
medical medical-devices
BTSG Drops 18.1% in One Week as Growth Meets Fresh Valuation Risks
by Urbi Guha
BrightSpring's 18.1% weekly slide clashes with strong growth and raised guidance as valuation, policy and integration risks test the rebound case.
BTSGNegative Net Change MCKPositive Net Change OPCHNegative Net Change
medical medical-devices
Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Up
by Zacks Equity Research
INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.
INSPPositive Net Change CAHPositive Net Change MCKPositive Net Change WSTPositive Net Change
earnings medical medical-devices
Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
by Zacks Equity Research
IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.
IQVPositive Net Change ICLRPositive Net Change MEDPPositive Net Change
medical medical-devices